In his first address to a joint session of Congress, Trump spoke of a need to "slash the restraints" at US FDA and other regulatory agencies, and he reminded legislators about his executive order to eliminate two regulations for each new one written. The president's anti-regulatory posture comes as the White House is expected to seek budget cuts for domestic agencies.
President Trump, in his first speech to a joint session Congress Feb. 28, criticized FDA's approval process as a barrier to new medical innovations.
In the context of praising a young woman, Megan Crowley, who had struggled all her life to overcome a rare disorder known as Pompe disease, and her father's efforts to...